Urovant Sciences

What Urovant Sciences does

Urovant Sciences is a global biopharmaceutical company, founded in 2017 and headquartered in Basel, Switzerland, that develops novel therapies for urologic conditions. The company is publicly listed on NASDAQ under the ticker UROV and sits within the Sumitomo Pharma group (parent: Sumitomo Pharma Co., Ltd.). Its core activity is drug discovery, development, and commercialization in urology and adjacent therapeutic areas, executed through a model that combines proprietary clinical assets with standard pharmaceutical distribution into healthcare-provider and patient channels. The firm employs between 101 and 250 people, with stated executive functions spanning chief medical officer, finance (CFO/SVP Business Development), accounting, and human resources — consistent with a transition from a clinical-stage developer to a commercially operating biopharma.

Functionally, Urovant monetizes through pharmaceutical product sales distributed via standard medical and healthcare channels, served to a primary customer segment composed of healthcare providers and patients seeking innovative treatments for unmet medical needs. Its stated value proposition centers on delivering differentiated medicines that address critical areas of unmet need (with the broader parent platform extending into oncology, women's health, rare disease, CNS, and cell & gene therapies). The company has supplemented its operating capital through at least one disclosed $100M debt financing led by Hercules Capital in February 2019, consistent with a development-and-commercialization funding profile.

No specific product names, pricing models, customer logos, or revenue figures are disclosed in the available inputs, limiting visibility into commercial scale. Marketing presence is built around organic social channels (LinkedIn, Twitter) and a corporate newsroom, targeting healthcare providers, patients, and caregivers as top-of-funnel audiences. No AI/ML capabilities, partnerships, awards, patents, or M&A events are documented in the source data.

Name

Urovant Sciences

Legal name

Sumitomo Pharma America, Inc.

Website

https://urovant.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Urovant Sciences is a global biopharmaceutical company (NASDAQ: UROV) founded in 2017 and based in Basel, Switzerland, developing novel therapies for urologic conditions as a subsidiary of Sumitomo Pharma, serving healthcare providers and patients.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Nephrology & Urology Pharmaceuticals (HLAIAAAM)

akta.pro secondary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Urologic therapies
• Biopharmaceutical drugs
• Specialty pharmaceuticals
• Drug development
• Urology treatments

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Marketing channels3 records

Core offering

Urovant Sciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies primarily for urologic conditions. Its product strategy includes a pipeline of preclinical and clinical programs addressing unmet medical needs in urology, oncology, women's health, rare disease, CNS, and cell & gene therapies, operating as part of the Sumitomo Pharma America portfolio.

Product overview

Sumitomo Pharma America (SMPA) is a pharmaceutical company focused on drug discovery, development, and commercialization across multiple therapeutic areas. The company maintains a diverse pipeline of preclinical and clinical programs and offers products in critical areas including oncology, women's health, urology, rare disease, CNS, and cell & gene therapies.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights5 records

Direct peers

• Astellas Pharma: Astellas markets mirabegron (Myrbetriq), the incumbent beta-3 agonist and direct head-to-head competitor of Urovant's vibegron (GEMTESA) in overactive bladder. Most directly comparable commercial competitor in the same mechanism and indication.
• Kyorin Pharmaceutical: Kyorin is the originator of vibegron and licensed it to Urovant. Comparable as a Japanese specialty pharma with a urology asset and co-development economics tied to Urovant's commercial success.
• Ferring Pharmaceuticals: Ferring is a privately held specialty pharma with a meaningful urology franchise (e.g., degarelix for prostate cancer, desmopressin). Comparable as a focused urology and reproductive health player with specialty detailing overlap.
• Tolmar Pharmaceuticals: Tolmar markets urology products including eligard (leuprolide) for prostate cancer. Comparable as a specialty urology-focused pharma with overlapping physician call points.

Broad incumbents

• AbbVie: Through its Allergan acquisition, AbbVie markets onabotulinumtoxinA (Botox) for OAB and other urology assets. A broad-line incumbent with overlapping OAB capability rather than a focused urology franchise.
• Pfizer: Pfizer has historically sold tolterodine (Detrol/Detrol LA) for OAB. A large incumbent pharma with prior OAB presence and broad primary-care distribution muscle that overlaps with Urovant's commercial channels.
• Coloplast: Coloplast has a urology business spanning continence care, catheters, and surgical urology. Adjacent incumbent sharing the same urology specialists and care pathways as Urovant.
• Merck & Co. Merck was involved in early development of vibegron through its relationship with Kyorin. As a large pharma incumbent with prior urology interest, it is a comparable large-cap reference point for Urovant's pipeline strategy.

Others

• Laborie Medical Technologies: Laborie is a urology-focused medical technology and diagnostics company. Comparable in targeting the same urology specialists though it operates in devices and diagnostics rather than branded pharma.
• Sumitomo Pharma (parent): Sumitomo Pharma Co., Ltd. is the parent corporation. As the controlling shareholder, its strategic and capital allocation decisions directly determine Urovant's trajectory and is the most directly relevant ecosystem participant.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/urovant
• LinkedInlinkedin.com/company/urovant-sciences-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Urovant Sciences